Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > An easy read on repurposing drugs.

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Jan 02, 2021 11:05pm

115 Views

Post# 32210693

RE:An easy read on repurposing drugs.

Here is a link to an Algernon article from April. Compare this to the link you just posted!

The drug was previously tested against H1N1, thus making the case for a Covid 19 treatment very weak.

https://midasletter.com/2020/04/ifenprodil-the-specialized-drug-treating-coronavirus/

look at how fast the South Korea trial ended, they just went to the pharmacy abs got the pills.... do you forget how they then shifted back to chronic cough? The Covid dream is over!

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec